Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA: Neoadjuvant Atezolizumab and Chemotherapy in Resectable Gastric and GEJ Cancer
NCT03448835Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2018
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Netherlands Cancer Institute. Started Mar 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03448835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448835.